DOC
Healthpeak Properties, Inc.Evidence as of 2026-09-02Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.0 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
Mixed. Revenues rose from $ 752,952,000 in Q1 2026 (fiscal quarter ended 2026-05-04) to $ 771,579,000 in Q2 2026 (fiscal quarter ended 2026-08-03), while reported net income fell from $ 193,633,000 in Q1 2026 to $ 52,817,000 in Q2 2026 and diluted EPS moved from $ 0.28 to $ 0.08 over the same two quarters. Balance-sheet and market snapshots show cash and cash equivalents increasing to $ 1,626,827,000 as of 2026-06-30, long-term debt around $ 10,032,186,000 as of 2026-06-30 (up from $ 9,847,894,000 at 2025-12-31 and peaked at $ 10,422,772,000 as of 2026-03-31), a market price of $ 21.03 per share on 2026-09-02, market capitalization of $ 14,500,758,278 and enterprise value of $ 22,906,117,278, and a trailing twelve-month P/E of 87.62 with EPS TTM of $ 0.24.
The evidence also records a modest decline in entity common shares outstanding from 695,043,997 as of 2026-01-30 (FY 2025) to 689,419,702 as of 2026-05-04 and 689,527,260 as of 2026-08-03, and notes limited ownership detail (a single ETF weight: 0.02% in IVV) and several news items and comparative articles published in late August and early September 2026.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenues were $752,952,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and increased to $771,579,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001628280-26-031287Net income was $193,633,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and fell to $52,817,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001628280-26-053373Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, the evidence shows DOC has a membership weight of 0.02% in the iShares Core S&P 500 ETF (IVV).
ETF constituents · market dataThe provided ownership evidence contains a single ETF membership record for DOC (the IVV entry) and does not include other ETF weights or institutional holdings.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A published interview with Healthpeak Properties' President and CEO Scott Brinker appeared on 1 September 2026 via Advisor Access and was carried on finance.yahoo.com.
News · finance.yahoo.com · 2026-09-01The same CEO interview was distributed on 1 September 2026 via GlobeNewswire.
News · globenewswire.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The market price used in this evidence is $21.03 per share as of 2026-09-02.
Valuation inputs · SEC XBRL + stored EOD closeMarket capitalization is $14,500,758,278 and enterprise value is $22,906,117,278 (price date 2026-09-02).
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The evidence set contains multiple company-specific signals that jointly support a favorable read. Revenues rose sequentially between Q1 and Q2 2026 while cash on the balance sheet materially increased and common shares outstanding declined, which together indicate improving liquidity per share and ongoing capital return or share count management. Positive media coverage and at least one newly reported institutional buyer provide supportive investor interest context that can complement the operational signs. Against the bear points (earnings volatility, elevated leverage and valuation metrics, missing FCF data), the strongest counter-evidence here is the cash build and share-count decline; these items are directly documented in the filings and moderately strengthen a constructive interpretation when combined with rising revenue.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.32
20 surviving claims rest on 11 distinct sources; the heaviest analyst carries 30% of them, and 100% of what the desk raised survived the debate.
The surviving read rests on a moderate diversity of sources but a relatively small analyst concentration — nearly a third of the claims come from one analyst and all desk challenges survived, so the set is resilient to casual critique but still sensitive to a few contributors. Source concentration and analyst dependence mean these claims can carry useful informational weight, yet they are fragile to a small number of contradictory filings or market datapoints that directly revise key inputs.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
12 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.0 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on DOC Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.